These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 7474077)

  • 1. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.
    Muster T; Ferko B; Klima A; Purtscher M; Trkola A; Schulz P; Grassauer A; Engelhardt OG; García-Sástre A; Palese P
    J Virol; 1995 Nov; 69(11):6678-86. PubMed ID: 7474077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract.
    Ferko B; Katinger D; Grassauer A; Egorov A; Romanova J; Niebler B; Katinger H; Muster T
    J Infect Dis; 1998 Nov; 178(5):1359-68. PubMed ID: 9780256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
    Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
    J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization.
    Durrani Z; McInerney TL; McLain L; Jones T; Bellaby T; Brennan FR; Dimmock NJ
    J Immunol Methods; 1998 Nov; 220(1-2):93-103. PubMed ID: 9839930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.
    Akagi T; Kawamura M; Ueno M; Hiraishi K; Adachi M; Serizawa T; Akashi M; Baba M
    J Med Virol; 2003 Feb; 69(2):163-72. PubMed ID: 12683403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus.
    Xin KQ; Urabe M; Yang J; Nomiyama K; Mizukami H; Hamajima K; Nomiyama H; Saito T; Imai M; Monahan J; Okuda K; Ozawa K; Okuda K
    Hum Gene Ther; 2001 Jun; 12(9):1047-61. PubMed ID: 11399227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.
    Sakaue G; Hiroi T; Nakagawa Y; Someya K; Iwatani K; Sawa Y; Takahashi H; Honda M; Kunisawa J; Kiyono H
    J Immunol; 2003 Jan; 170(1):495-502. PubMed ID: 12496436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.
    Zhang H; Huang Y; Fayad R; Spear GT; Qiao L
    J Virol; 2004 Aug; 78(15):8342-8. PubMed ID: 15254206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
    J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160.
    VanCott TC; Kaminski RW; Mascola JR; Kalyanaraman VS; Wassef NM; Alving CR; Ulrich JT; Lowell GH; Birx DL
    J Immunol; 1998 Feb; 160(4):2000-12. PubMed ID: 9469464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.
    Muster T; Guinea R; Trkola A; Purtscher M; Klima A; Steindl F; Palese P; Katinger H
    J Virol; 1994 Jun; 68(6):4031-4. PubMed ID: 7514684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus.
    Garulli B; Kawaoka Y; Castrucci MR
    J Virol; 2004 Jan; 78(2):1020-5. PubMed ID: 14694134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.
    Kang SM; Guo L; Yao Q; Skountzou I; Compans RW
    J Virol; 2004 Sep; 78(18):9624-32. PubMed ID: 15331695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine.
    Yao Q; Zhang R; Guo L; Li M; Chen C
    J Immunol; 2004 Aug; 173(3):1951-8. PubMed ID: 15265929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses.
    Kato H; Bukawa H; Hagiwara E; Xin KQ; Hamajima K; Kawamoto S; Sugiyama M; Sugiyama M; Noda E; Nishizaki M; Okuda K
    Vaccine; 2000 Jan; 18(13):1151-60. PubMed ID: 10649615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA.
    Marinaro M; Riccomi A; Rappuoli R; Pizza M; Fiorelli V; Tripiciano A; Cafaro A; Ensoli B; De Magistris MT
    Vaccine; 2003 Sep; 21(25-26):3972-81. PubMed ID: 12922133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques.
    Chikhlikar P; Barros de Arruda L; Maciel M; Silvera P; Lewis MG; August JT; Marques ET
    PLoS One; 2006 Dec; 1(1):e135. PubMed ID: 17205139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
    Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
    Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.